AmeriPharma’s premier pharmacy services are available in multiple states throughout the US.

Related Posts

HYQVIA for SubQ IG Therapy 

Home  /  IVIg   /  HYQVIA for SubQ IG Therapy 

HYQVIA for SubQ IG Therapy 

Trade name: HYQVIA

Manufacturer: Baxter Healthcare Corporation, Baxter BioScience

Alternatives: Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase


Get your Hyqvia Dose – Speak to a Specialist

(877) 778-0318


What is HYQVIA?

HYQVIA is an injectable drug containing a genetically designed protein. It is a dual vial unit with a vial of Immune globulin infusion 10% (Ig) and another vial of recombinant human hyaluronidase (Hy), which assists your body in the absorption of injectable medicines.


The parts are infused one after the other (Hy first, Ig second) through a needle set.




HYQVIA is an immune globulin infusion. It is a sterilized solution made up of human plasma containing antibodies that help your body to protect itself against different infectious diseases. It is used in treating primary immunodeficiency in adults. 




HYQVIA is administered in the form of a subcutaneous infusion, given under the skin. It has flexible administration options in which a healthcare provider can teach you how to self-administer in the comfort of your own home. 


Do not self-administer the medication if you do not understand the instructions properly. The infusion can also be administered at an infusion center. 



  • HYQVIA is to be stored in a refrigerator 36° to 46° for up to 3 years, (do not freeze the medication)
  • It may be stored at room temperature (up to 77°F) for up to 3 months, during the first 24 months from the date of manufacturing printed on the carton. 
  • Do not return HYQVIA to the refrigerator if you take it out to room temperature. 
  • Store HYQVIA in its carton to protect it from light. 
  • The refrigerated product should be allowed to come to room temperature before use. 
  • Do not heat or microwave the product. 



For infusion, an infusion pump is needed to titrate the appropriate flow rate. To prevent leakage at the infusion site while administering Hyqvia, a longer needle (12 or 14 mm) and using multiple infusion sites are considered


  • Before infusing, inspect the vials for any cloudy precipitates and do not shake the vials
  • Do not use the medication if the solution is not clear. 
  • Each vial is single-use and should not be used more than once.
  • Suggested infusion sites are the thighs or abdomen
  • When infusing, do not mix the two medications given in the HYQVIA kit


Infused Sequentially


Both the components of HYQVIA are infused sequentially, starting first with Hyaluronidase then Ig 10% within 10 minutes through the same subcutaneous needle. 


The entire contents of the Hyaluronidase vial are used for each full or partial vial of Ig infusion.   


Local infusion-site reactions such as mild to moderate pain, temporary soft pancake-like swelling, itching, and skin redness are common. 


Swelling may last 1-3 days and infusion-related reactions should go away in a few hours.


HYQVIA Copay Assistance Available

Learn More




Do not use HYQVIA If you ever had an allergic reaction to Immune globulin, human albumin, and hyaluronidase, or if you are Immunoglobulin A deficient



Warnings and Precautions

HYQVIA can cause blood clots, especially if you are 65 years or older, have heart disease, circulation disease, or have a history of blood clots. 


Immediately contact your provider if you experience sudden chest pain, numbness, slurred speech, vision disorder, shortness of breath or pain, warmth, or swelling in the leg or arm. 


Inform your health care professional before administering infusion if you have any other health conditions such as diabetes, kidney disease, pregnancy, or dehydration. Do not infuse into or around an infected area as it may cause the infection to spread.



Drug Interactions

HYQVIA may interact and interfere with the immune responses to live virus vaccines, such as measles/mumps/rubella (MMR) and chickenpox



Side Effects

According to clinical trials, >5% of the subjects experienced some common side effects including headache, fever, vomiting, nausea, fatigue, antibody formation against hyaluronidase, and symptoms of allergy such as swelling, itching, pain, and skin rash. There is no evidence of skin damage from HYQVIA so far.


HYQVIA can cause blood clots or thrombosis. Get immediate medical assistance if you experience any of the following adverse effects:

  • Speech and vision problems
  •  Sudden numbness and lethargy
  • Chest pain
  • Blood in cough
  • Dark urine
  • Decreased urination
  • Jaundice
  • Infection
  • Fast heartbeat
  • Blood clotting in arm or leg
  • Pulmonary disease such as transfusion-related acute lung injury (TRALI)


Home Infusion Available

Get a Free Evaluation



The dosing of HYQVIA is on an individualized basis.

HYQVIA dosing variation is discussed below:

  • If the patient already takes Ig infusions, the treatment should be initiated 1 week after the last Ig infusion.
  • Gradually increase dosage and frequency from a 1-week dose to a 3- or 4-week dose
  • The initial dose is 7.5g on week 1, 15g on week 2,  22.5g on week 4, then 30g on week 7 (see the full information in HYQVIA package insert)
  • If the patient has switched from IVIG treatment then administer HYQVIA at the same dose and frequency as previous IV treatment after initial dose ramp-up
  • If the patient has switched from SCIG treatment or is  IgG-naïve then administer at 300–600mg/kg at 3–4 week intervals after initial ramp-up can be administered
  • If the patient is at high risk of renal failure or thrombosis then administer HYQVIA at the minimum dose and infusion rate practicable



What should be the volume per site:

Up to 600 mL per site can be administered for patients who weigh 40kg or more and up to 300 mL each site for those who weigh less than 40 kg.


What should be the rate of infusion:

Administer the Hyaluronidase of HYQVIA at an initial rate per site of approximately 1 to 2 mL per minute or as tolerated.




HYQVIA is mainly indicated for treating primary immunodeficiency (PI) in adults. 

Immunodeficiency conditions may include common variable immunodeficiency, Wiskott-Aldrich syndrome, congenital or X-linked agammaglobulinemia, and severe combined immunodeficiencies.



The average cost for HYQVIA subcutaneous solution (160 units/mL-10%) is approximately $567 for a supply of 26.25 milliliters and $21.59/unit. This price may vary depending on the pharmacy.


Copay Assistance

Certain programs offer assistance with the cost of HYQVIA. Offers may be in different forms including a printable coupon, rebate, trial offer, savings card, or free samples. Some offers may be printed directly from a website, others require proper enrollment, completing a questionnaire, or obtaining a sample from the provider’s office. 

The copay assistance programs include:

  • HYQVIA OnePath Co-Pay Assistance Program
  • HYQVIA HelloHYQVIA Free Trial Offer
  • HealthWell Foundation Copay Program
  • Patient Access Network Foundation (PAN)
  • OnePath Patient Assistance Program (HYQVIA)


 Note: All the above-mentioned programs have different eligibility requirements.


HYQVIA vs Hizentra

Hizentra is indicated for primary immunodeficiency syndrome and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).


Hizentra is used as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older.


Hizentra may also be used for other diagnoses. Hizentra subcutaneous injection (5ml units/mL-20%) is approximately $209.01 for a supply of 5 milliliters and $41.80/unit. 


This price may vary depending on the pharmacy. 


Pros of HYQVIA vs. Hizentra

  • Lower cost per mL vs. Hizentra
  • Infused every 3-4 weeks
  • 1-2 infusion sites


Cons of HYQVIA vs. Hizentra

  • Only FDA approved to treat primary immunodeficiency
  • Must infuse two components: Hy and Ig
  • More fluid to infuse
  • Longer infusion time